User profiles for Sofia Agelaki
 | Sofia AgelakiProfessor of Medical Oncology, School of Medicine, University of Crete Verified email at med.uoc.gr Cited by 8852 |
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
Background We aimed to assess the clinical validity of circulating tumour cell (CTC) quantification
for prognostication of patients with metastatic breast cancer by undertaking a pooled …
for prognostication of patients with metastatic breast cancer by undertaking a pooled …
Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer
PA Theodoropoulos, H Polioudaki, S Agelaki… - Cancer letters, 2010 - Elsevier
The CD44 + /CD24 −/low and ALDH1 + cell phenotypes are associated with stemness and
enhanced tumorigenic potential in breast cancer. We assessed the expression of CD44, …
enhanced tumorigenic potential in breast cancer. We assessed the expression of CD44, …
Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer
…, M Perraki, K Kalbakis, S Agelaki… - Journal of Clinical …, 2009 - ascopubs.org
Purpose To evaluate the prognostic significance of cytokeratin-19 (CK-19) mRNA-positive
circulating tumor cells (CTCs) in peripheral blood of women with early-stage breast cancer …
circulating tumor cells (CTCs) in peripheral blood of women with early-stage breast cancer …
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
Background The heterogeneity of metastatic breast cancer (MBC) necessitates novel
biomarkers allowing stratification of patients for treatment selection and drug development. We …
biomarkers allowing stratification of patients for treatment selection and drug development. We …
Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in …
Corticotropin-releasing hormone (CRH) exerts an anti-inflammatory effect indirectly, via
cortisole production, and a proinflammatory effect directly on immune cells. The aim of the …
cortisole production, and a proinflammatory effect directly on immune cells. The aim of the …
Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer
…, D Mavroudis, V Georgoulias, S Agelaki - Molecular Cancer …, 2019 - AACR
Circulating tumor cells (CTCs) bearing phenotypes related to cancer stem cells (CSCs) and
epithelial-to-mesenchymal transition (EMT) have been identified in breast cancer; however, …
epithelial-to-mesenchymal transition (EMT) have been identified in breast cancer; however, …
[HTML][HTML] Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and …
H Polioudaki, S Agelaki, R Chiotaki, E Politaki… - BMC cancer, 2015 - Springer
Background CTCs expressing variable levels of epithelial and mesenchymal markers in
breast cancer have previously been reported. However, no information exists for keratin …
breast cancer have previously been reported. However, no information exists for keratin …
[HTML][HTML] Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients
G Kallergi, S Agelaki, A Kalykaki, C Stournaras… - Breast cancer …, 2008 - Springer
Introduction The phosphoinositide-3 kinase (PI3K)/Akt pathway, operating downstream of
epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER)2, …
epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER)2, …
[HTML][HTML] Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients
…, V Georgoulias, D Mavroudis, S Agelaki - Breast Cancer …, 2009 - Springer
Introduction The detection of peripheral blood circulating tumor cells (CTCs) and bone
marrow disseminated tumor cells (DTCs) in breast cancer patients is associated with a high …
marrow disseminated tumor cells (DTCs) in breast cancer patients is associated with a high …
Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 …
…, P Papakotoulas, A Rapti, M Agelidou, S Agelaki… - Cancer, 2013 - Wiley Online Library
BACKGROUND In this superiority study, pemetrexed was compared with erlotinib in pre‐treated
patients with metastatic non–small cell lung cancer (NSCLC). METHODS Patients with …
patients with metastatic non–small cell lung cancer (NSCLC). METHODS Patients with …